Liver Protein MLKL Drives Aging Through Mitochondrial Damage and Cellular Senescence
A liver-specific protein triggers aging not through cell death, but by spreading senescence via mitochondrial dysfunction and inflammatory signals.
Summary
Researchers discovered that MLKL, a protein previously known for its role in inflammatory cell death, has a surprising second job in liver aging. When elevated in liver cells, MLKL doesn't kill them — instead it impairs mitochondria, generates oxidative stress, and triggers cellular senescence, a state where cells stop dividing but pump out inflammatory signals. These senescent cells then release extracellular vesicles that spread the senescent state to neighboring cells, including immune macrophages, amplifying liver inflammation. The findings identify MLKL as a key driver of age-related liver disease and a potential drug target for conditions like fatty liver disease associated with aging.
Detailed Summary
Liver aging is a slow-burning crisis that underpins a growing epidemic of metabolic liver disease, yet its molecular drivers remain incompletely understood. This study illuminates an unexpected mechanism: a protein called MLKL, best known for executing inflammatory cell death (necroptosis), appears to accelerate liver aging through an entirely different route — one that doesn't kill cells but instead leaves them dysfunctional and inflammatory.
Researchers at the University of Oklahoma engineered mice with liver-cell-specific overexpression of MLKL to model elevated MLKL levels observed in aged livers. Critically, despite high MLKL levels, hepatocytes did not undergo necroptosis. Instead, cells showed hallmarks of senescence — elevated p16INK4a and p21 markers — along with a senescence-associated secretory phenotype (SASP), a cocktail of pro-inflammatory signals that damage surrounding tissue.
The mechanistic chain was clear: elevated MLKL impaired mitochondrial respiration, disrupted mitochondrial dynamics, and increased reactive oxygen species (ROS). This oxidative stress then drove cells into senescence and triggered release of pro-inflammatory extracellular vesicles (EVs), which spread senescence to neighboring non-parenchymal cells. Macrophages emerged as particularly senescence-enriched, suggesting they amplify inflammatory signaling throughout the liver.
These findings reframe MLKL from a simple executioner of cell death into a broader regulator of liver inflammaging — the chronic, low-grade inflammation that characterizes aged tissue. The MLKL-mitochondria-senescence axis may help explain why older livers are especially prone to metabolic dysfunction-associated steatotic liver disease (MASLD).
The study suggests MLKL inhibition in hepatocytes could be a viable therapeutic strategy to slow liver aging and reduce MASLD progression. However, since findings derive from a mouse overexpression model and abstract-level data, translational validation in human tissue and disease models will be essential before clinical applications can be pursued.
Key Findings
- MLKL protein is elevated in aged liver cells and drives senescence without triggering cell death.
- Elevated hepatocyte MLKL impairs mitochondrial respiration and increases reactive oxygen species.
- MLKL-driven mitochondrial dysfunction triggers SASP, spreading senescence to neighboring liver cells.
- Macrophages become highly senescence-enriched, amplifying liver-wide inflammation via paracrine signaling.
- MLKL inhibition is identified as a potential therapeutic target for age-related liver disease and MASLD.
Methodology
Researchers used hepatocyte-specific MLKL-overexpressing transgenic mice (MLKLHepOE) to isolate liver-cell-specific effects of elevated MLKL. Senescence markers (p16INK4a, p21), mitochondrial function, ROS levels, extracellular vesicle profiles, and SASP components were assessed across hepatocytes and non-parenchymal cells. The study combined proteomics, transcriptomics, and cell biology approaches across multiple institutional collaborators.
Study Limitations
This summary is based on the abstract only; full methodological details, data figures, and statistical analyses were not available for review. Findings are from a mouse overexpression model, which may not precisely recapitulate the gradual MLKL elevation seen in human aging. Causal validation in human liver tissue and disease cohorts is needed before clinical translation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: